Top Key Companies for Angiogenesis Modulators Market: F.Hoffmann-La Roche Ltd, Aeterna Zentaris Inc, Abbott Laboratories, Merck & Co., Inc., GlaxoSmithKline plc, Amgen, Inc., Entremed, Inc, Celgene Corporation, Alcon, Inc., Antisoma plc, Eisai, Inc., Progen Pharmaceuticals Ltd., OXiGENE, Inc., Eye-Tech Inc, Genvec, Inc, Eli Lilly and Company, Imclone Systems, Inc., Chugai Pharmaceutical Co., Ltd., Merck KGaA, Cardium Therapeutics, Inc, Bristol-Myers Squibb Company, Ångstrom Pharmaceuticals, Inc., Bayer Healthcare AG, Genentech, Inc., Angiotech Pharmaceuticals, Inc., Silence Therapeutics plc, Astrazeneca plc, Genzyme Corporation, ThromboGenics, Inc.
Global Angiogenesis Modulators Market Research Report: 2025-2032 Outlook with Market Insights, Industry and Competitive Analysis Included. Remarkable growth trajectory projected.
Global Angiogenesis Modulators Market Overview And Scope:
The Global Angiogenesis Modulators Market Report 2025 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Angiogenesis Modulators utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2025 and 2032. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
Global Angiogenesis Modulators Market Segmentation
By Type, Angiogenesis Modulators market has been segmented into:
Angiogenesis Inhibitors
Angiogenesis Stimulators
Angiogenin
Others
By Application, Angiogenesis Modulators market has been segmented into:
Cancer
Cardiology
Ophthalmology
Others
Regional Analysis of Angiogenesis Modulators Market:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape of Angiogenesis Modulators Market:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Angiogenesis Modulators market study focused on including all the primary level, secondary level and tertiary level competitors in the report.The data generated by conducting the primary and secondary research. The report covers detail analysis of driver, constraints and scope for new players entering the Angiogenesis Modulators market.
Top Key Companies Covered in Angiogenesis Modulators market are:
F.Hoffmann-La Roche Ltd
Aeterna Zentaris Inc
Abbott Laboratories
Merck & Co.
Inc.
GlaxoSmithKline plc
Amgen
Inc.
Entremed
Inc
Celgene Corporation
Alcon
Inc.
Antisoma plc
Eisai
Inc.
Progen Pharmaceuticals Ltd.
OXiGENE
Inc.
Eye-Tech Inc
Genvec
Inc
Eli Lilly and Company
Imclone Systems
Inc.
Chugai Pharmaceutical Co.
Ltd.
Merck KGaA
Cardium Therapeutics
Inc
Bristol-Myers Squibb Company
Ångstrom Pharmaceuticals
Inc.
Bayer Healthcare AG
Genentech
Inc.
Angiotech Pharmaceuticals
Inc.
Silence Therapeutics plc
Astrazeneca plc
Genzyme Corporation
ThromboGenics
Inc
Key Questions answered in the Angiogenesis Modulators Market Report:
1. What is the expected Angiogenesis Modulators Market size during the forecast period, 2025-2032?
2. Which region is the largest market for the Angiogenesis Modulators Market?
3. What is the expected future scenario and the revenue generated by different regions and countries in the Angiogenesis Modulators Market, such as North America, Europe, AsiaPacific & Japan, China, U.K., South America, and Middle East and Africa?
4. What is the competitive strength of the key players in the Angiogenesis Modulators Market on the basis of the analysis of their recent developments, product offerings, and regional presence?
5. Where do the key Angiogenesis Modulators companies lie in their competitive benchmarking compared to the factors of market coverage and market potential?
6. How are the adoption scenario, related opportunities, and challenges impacting the Angiogenesis Modulators Markets?
7. How is the funding and investment landscape in the Angiogenesis Modulators Market?
8. Which are the leading consortiums and associations in the Angiogenesis Modulators Market, and what is their role in the market?
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Angiogenesis Modulators Market by Type
5.1 Angiogenesis Modulators Market Overview Snapshot and Growth Engine
5.2 Angiogenesis Modulators Market Overview
5.3 Angiogenesis Inhibitors
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Angiogenesis Inhibitors: Geographic Segmentation
5.4 Angiogenesis Stimulators
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Angiogenesis Stimulators: Geographic Segmentation
5.5 Angiogenin
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Angiogenin: Geographic Segmentation
5.6 Others
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Others: Geographic Segmentation
Chapter 6: Angiogenesis Modulators Market by Application
6.1 Angiogenesis Modulators Market Overview Snapshot and Growth Engine
6.2 Angiogenesis Modulators Market Overview
6.3 Cancer
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Cancer: Geographic Segmentation
6.4 Cardiology
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Cardiology: Geographic Segmentation
6.5 Ophthalmology
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Ophthalmology: Geographic Segmentation
6.6 Others
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size (2017-2032F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Others: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Angiogenesis Modulators Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Angiogenesis Modulators Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Angiogenesis Modulators Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 F.HOFFMANN-LA ROCHE LTD
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 AETERNA ZENTARIS INC
7.4 ABBOTT LABORATORIES
7.5 MERCK & CO.
7.6 INC.
7.7 GLAXOSMITHKLINE PLC
7.8 AMGEN
7.9 INC.
7.10 ENTREMED
7.11 INC
7.12 CELGENE CORPORATION
7.13 ALCON
7.14 INC.
7.15 ANTISOMA PLC
7.16 EISAI
7.17 INC.
7.18 PROGEN PHARMACEUTICALS LTD.
7.19 OXIGENE
7.20 INC.
7.21 EYE-TECH INC
7.22 GENVEC
7.23 INC
7.24 ELI LILLY AND COMPANY
7.25 IMCLONE SYSTEMS
7.26 INC.
7.27 CHUGAI PHARMACEUTICAL CO.
7.28 LTD.
7.29 MERCK KGAA
7.30 CARDIUM THERAPEUTICS
7.31 INC
7.32 BRISTOL-MYERS SQUIBB COMPANY
7.33 ÅNGSTROM PHARMACEUTICALS
7.34 INC.
7.35 BAYER HEALTHCARE AG
7.36 GENENTECH
7.37 INC.
7.38 ANGIOTECH PHARMACEUTICALS
7.39 INC.
7.40 SILENCE THERAPEUTICS PLC
7.41 ASTRAZENECA PLC
7.42 GENZYME CORPORATION
7.43 THROMBOGENICS
7.44 INC
Chapter 8: Global Angiogenesis Modulators Market Analysis, Insights and Forecast, 2017-2032
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Angiogenesis Inhibitors
8.2.2 Angiogenesis Stimulators
8.2.3 Angiogenin
8.2.4 Others
8.3 Historic and Forecasted Market Size By Application
8.3.1 Cancer
8.3.2 Cardiology
8.3.3 Ophthalmology
8.3.4 Others
Chapter 9: North America Angiogenesis Modulators Market Analysis, Insights and Forecast, 2017-2032
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Angiogenesis Inhibitors
9.4.2 Angiogenesis Stimulators
9.4.3 Angiogenin
9.4.4 Others
9.5 Historic and Forecasted Market Size By Application
9.5.1 Cancer
9.5.2 Cardiology
9.5.3 Ophthalmology
9.5.4 Others
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Angiogenesis Modulators Market Analysis, Insights and Forecast, 2017-2032
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Angiogenesis Inhibitors
10.4.2 Angiogenesis Stimulators
10.4.3 Angiogenin
10.4.4 Others
10.5 Historic and Forecasted Market Size By Application
10.5.1 Cancer
10.5.2 Cardiology
10.5.3 Ophthalmology
10.5.4 Others
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Angiogenesis Modulators Market Analysis, Insights and Forecast, 2017-2032
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Angiogenesis Inhibitors
11.4.2 Angiogenesis Stimulators
11.4.3 Angiogenin
11.4.4 Others
11.5 Historic and Forecasted Market Size By Application
11.5.1 Cancer
11.5.2 Cardiology
11.5.3 Ophthalmology
11.5.4 Others
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Angiogenesis Modulators Market Analysis, Insights and Forecast, 2017-2032
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Angiogenesis Inhibitors
12.4.2 Angiogenesis Stimulators
12.4.3 Angiogenin
12.4.4 Others
12.5 Historic and Forecasted Market Size By Application
12.5.1 Cancer
12.5.2 Cardiology
12.5.3 Ophthalmology
12.5.4 Others
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Angiogenesis Modulators Market Analysis, Insights and Forecast, 2017-2032
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Angiogenesis Inhibitors
13.4.2 Angiogenesis Stimulators
13.4.3 Angiogenin
13.4.4 Others
13.5 Historic and Forecasted Market Size By Application
13.5.1 Cancer
13.5.2 Cardiology
13.5.3 Ophthalmology
13.5.4 Others
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Angiogenesis Modulators Market Analysis, Insights and Forecast, 2017-2032
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Angiogenesis Inhibitors
14.4.2 Angiogenesis Stimulators
14.4.3 Angiogenin
14.4.4 Others
14.5 Historic and Forecasted Market Size By Application
14.5.1 Cancer
14.5.2 Cardiology
14.5.3 Ophthalmology
14.5.4 Others
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Angiogenesis Modulators Scope:
|
Report Data
|
Angiogenesis Modulators Market
|
|
Angiogenesis Modulators Market Size in 2025
|
USD XX million
|
|
Angiogenesis Modulators CAGR 2025 - 2032
|
XX%
|
|
Angiogenesis Modulators Base Year
|
2024
|
|
Angiogenesis Modulators Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
F.Hoffmann-La Roche Ltd, Aeterna Zentaris Inc, Abbott Laboratories, Merck & Co., Inc., GlaxoSmithKline plc, Amgen, Inc., Entremed, Inc, Celgene Corporation, Alcon, Inc., Antisoma plc, Eisai, Inc., Progen Pharmaceuticals Ltd., OXiGENE, Inc., Eye-Tech Inc, Genvec, Inc, Eli Lilly and Company, Imclone Systems, Inc., Chugai Pharmaceutical Co., Ltd., Merck KGaA, Cardium Therapeutics, Inc, Bristol-Myers Squibb Company, Ångstrom Pharmaceuticals, Inc., Bayer Healthcare AG, Genentech, Inc., Angiotech Pharmaceuticals, Inc., Silence Therapeutics plc, Astrazeneca plc, Genzyme Corporation, ThromboGenics, Inc.
|
|
Key Segments
|
By Type
Angiogenesis Inhibitors
Angiogenesis Stimulators
Angiogenin
Others
By Applications
Cancer
Cardiology
Ophthalmology
Others
|
